A single center for supporting clinical research (CT) has been operating in Moscow for two years now – the Department of Clinical Research of the Moscow Center for Innovative Technologies in Healthcare. During this period of time, the department accepted and processed 78 applications for drug research in 16 therapeutic areas received from 15 pharmaceutical companies. All applications were accepted and the companies received full support for them. This was reported by the ANO “Moscow Center for Innovative Technologies in Health Care”.
The most common therapeutic areas: oncology, hematology, immunoprophylaxis, rheumatology, endocrinology and orphan diseases. Studies of the drug commissioned by companies are carried out in leading clinics in Moscow. This is the Loginov Moscow Clinical Scientific Center, Moscow City Oncology Hospital No 62, City Clinical Hospital №1 named after N.I. Pirogov, the Kommunarka Moscow Multidisciplinary Clinical Center (MMCC), City Clinical Hospital No. 15 named after O.M. Filatov.
“Moscow plays a significant role in the rapid development of domestic biotechnologies. Since the beginning of this year alone, 12 applications from 5 pharmaceutical companies have been processed for organizational support for research in the field of oncology, rheumatology and orphan diseases, and financial support has been provided for the development of 5 unique drugs aimed at treating diseases. approved in the field of oncology, neurology and rheumatology,” said Anastasia Rakova, Deputy Mayor of Moscow in the Moscow Government for Social Development.
